BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16981908)

  • 1. DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 proteins in a target site-dependent manner.
    Pivonková H; Pecinka P; Cesková P; Fojta M
    FEBS J; 2006 Oct; 273(20):4693-706. PubMed ID: 16981908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding.
    Patel S; Bui TT; Drake AF; Fraternali F; Nikolova PV
    Biochemistry; 2008 Mar; 47(10):3235-44. PubMed ID: 18260640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redox state of p63 and p73 core domains regulates sequence-specific DNA binding.
    Tichý V; Navrátilová L; Adámik M; Fojta M; Brázdová M
    Biochem Biophys Res Commun; 2013 Apr; 433(4):445-9. PubMed ID: 23501101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cadmium, cobalt and nickel on sequence-specific DNA binding of p63 and p73 in vitro and in cells.
    Adámik M; Bažantová P; Navrátilová L; Polášková A; Pečinka P; Holaňová L; Tichý V; Brázdová M
    Biochem Biophys Res Commun; 2015 Jan; 456(1):29-34. PubMed ID: 25446071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity.
    Sauer M; Bretz AC; Beinoraviciute-Kellner R; Beitzinger M; Burek C; Rosenwald A; Harms GS; Stiewe T
    Nucleic Acids Res; 2008 Apr; 36(6):1900-12. PubMed ID: 18267967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 and p73 display common and distinct requirements for sequence specific binding to DNA.
    Lokshin M; Li Y; Gaiddon C; Prives C
    Nucleic Acids Res; 2007; 35(1):340-52. PubMed ID: 17170001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structures of the DNA-binding domain tetramer of the p53 tumor suppressor family member p73 bound to different full-site response elements.
    Ethayathulla AS; Nguyen HT; Viadiu H
    J Biol Chem; 2013 Feb; 288(7):4744-54. PubMed ID: 23243311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence Variation in the Response Element Determines Binding by the Transcription Factor p73.
    Ramos A; Tse PW; Wang J; Ethayathulla AS; Viadiu H
    Biochemistry; 2015 Dec; 54(47):6961-72. PubMed ID: 26529454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach?
    Zawacka-Pankau J; Kostecka A; Sznarkowska A; Hedström E; Kawiak A
    Cell Cycle; 2010 Feb; 9(4):720-8. PubMed ID: 20160513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for ASPP2 recognition by the tumor suppressor p73.
    Canning P; von Delft F; Bullock AN
    J Mol Biol; 2012 Nov; 423(4):515-27. PubMed ID: 22917970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p73 is transcriptionally regulated by DNA damage, p53, and p73.
    Chen X; Zheng Y; Zhu J; Jiang J; Wang J
    Oncogene; 2001 Feb; 20(6):769-74. PubMed ID: 11314010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure of p73 DNA-binding domain tetramer modulates p73 transactivation.
    Ethayathulla AS; Tse PW; Monti P; Nguyen S; Inga A; Fronza G; Viadiu H
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6066-71. PubMed ID: 22474346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code.
    Ciribilli Y; Monti P; Bisio A; Nguyen HT; Ethayathulla AS; Ramos A; Foggetti G; Menichini P; Menendez D; Resnick MA; Viadiu H; Fronza G; Inga A
    Nucleic Acids Res; 2013 Oct; 41(18):8637-53. PubMed ID: 23892287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperation between p53 and p73 in cisplatin-induced apoptosis in ovarian carcinoma cells.
    Righetti SC; Perego P; Carenini N; Zunino F
    Cancer Lett; 2008 May; 263(1):140-4. PubMed ID: 18261847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73.
    Robinson RA; Lu X; Jones EY; Siebold C
    Structure; 2008 Feb; 16(2):259-68. PubMed ID: 18275817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73.
    van Dieck J; Brandt T; Teufel DP; Veprintsev DB; Joerger AC; Fersht AR
    Oncogene; 2010 Apr; 29(14):2024-35. PubMed ID: 20140014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis of the interactions between the p73 N terminus and p300: effects on transactivation and modulation by phosphorylation.
    Burge S; Teufel DP; Townsley FM; Freund SM; Bycroft M; Fersht AR
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3142-7. PubMed ID: 19218448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dimerization of the core domain of the p53 family: a computational study.
    Madhumalar A; Jun LH; Lane DP; Verma CS
    Cell Cycle; 2009 Jan; 8(1):137-48. PubMed ID: 19106606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of mutant p53 with p73: a Surface Plasmon Resonance and Atomic Force Spectroscopy study.
    Santini S; Di Agostino S; Coppari E; Bizzarri AR; Blandino G; Cannistraro S
    Biochim Biophys Acta; 2014 Jun; 1840(6):1958-64. PubMed ID: 24576672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.